
|Articles|October 4, 2007
Company files new drug application for topical ED treatment
NexMed, Inc., a developer of transdermal products based on its proprietary NexACT drug delivery technology, has filed a new drug application for its topically applied alprostadil cream for the treatment of erectile dysfunction.
Advertisement
NexMed, Inc., a developer of transdermal products based on its proprietary NexACT drug delivery technology, has filed a new drug application for its topically applied alprostadil cream for the treatment of erectile dysfunction.
The company said it is also working with various pharmaceutical companies to explore the incorporation of NexACT into their existing drugs as a means of developing new patient-friendly transdermal products.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix
5











